These medications belong to the GLP-1 receptor agonist class and help regulate blood sugar by enhancing insulin secretion, reducing glucagon release, slowing gastric emptying, and promoting weight loss
Products marketed as personalized blends with added vitamins or other ingredients, without a clear clinical rationale, are often designed to tout those additions to sidestep regulations rather than to benefit the patient
Participants began losing weight by the four-week mark, and this trend continued throughout the study period
This could involve temporarily reducing the dose, switching to a different GLP-1 receptor agonist with a different pharmacokinetic profile, or investigating whether concurrent medications contribute to tiredness
Some even go as far to say that, not only will incremental volumes be lower (as a more significant percentage will be won by orals) but also that orals will cannibalize the existing injectable volumes (so not only not a tailwind to future volumes, but also a headwind to existing volumes)
This recalibration of appetite neurobiology supports weight loss without the fatigue or muscle loss common with extreme calorie restriction
